NDAINJECTIONINJECTABLEPriority Review
Approved
Feb 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Priority Review
FERRLECIT (sodium ferric gluconate complex) by Sanofi. Approved for parenteral iron replacement [epc]. First approved in 1999.
Drug data last refreshed 12h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FERRLECIT is a parenteral iron replacement therapy approved in 1999 for treating iron deficiency anemia in patients who cannot tolerate or absorb oral iron. Administered by injection, it delivers sodium ferric gluconate complex to rapidly replenish iron stores in deficient patients. The product serves a critical role in dialysis and chronic disease populations requiring parenteral iron supplementation.
LOE Approaching
Product is approaching loss of exclusivity with modest competitive pressure (30/100), suggesting a contracting brand team focused on defending share in specialty markets.
Mechanism of Action
Pharmacologic Class:
Parenteral Iron Replacement
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.
Started Dec 2003
112 enrolled
Anemia
Career Relevance
FERRLECIT offers limited career expansion opportunities due to its mature lifecycle and approaching loss of exclusivity. Positions on this brand emphasize defensive commercialization, channel optimization, and specialty market penetration rather than innovation or growth.
Brand Manager
Worked on FERRLECIT at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.